ChemoFX May Predict Effectiveness of Cetuximab for Individual Colorectal Cancer Patients
June 4, 2009
Precision Therapeutics presentated data demonstrating the use of ChemoFX(R), a chemosensitivity assay, to predict the effectiveness of cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual patients. Results of the study were consistant with the reported clinical response rate for cetuximab in colorectal carcinoma patients. A predictive assay such as this could give physicians the edge they need to determine if cetuximab is appropriate for a patient before administering the biologic. ChemoFx(R) provides valuable insights that can help guide physicians' treatment decisions and give both physicians and patients an edge against cancer. Learn more at http://www.precisiontherapeutics.com/.
« Carnegie Learning: "Best in Tech" | | TOA and Amdocs Partner for Enhanced Customer Care »
